Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects by Terai, Naim et al.
© 2011 Terai et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2011:5 517–525
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
517
OriginAL reseArCh
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/OPTH.S18849
short-term effect of topical antiglaucoma 
medication on tear-film stability, tear secretion, 
and corneal sensitivity in healthy subjects
naim Terai
Matthias Müller-holz
eberhard spoerl
Lutz e Pillunat
Department of Ophthalmology, Carl 
gustav Carus University hospital, 
Dresden, germany
Correspondence: naim Terai 
Department of Ophthalmology, Carl 
gustav Carus University hospital, 
Fetscherstr 74, Dresden 01307, germany 
Tel +49 351 458 5091 
Fax +49 351 458 4335 
email naim.terai@uniklinikum-dresden.de
Background: The purpose of this study was to investigate the short-term effect of topical 
antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy 
subjects.
Methods: In this prospective, double-blind crossover trial, break-up time and basal   secretion 
(Jones test) were measured 60 minutes before, and 30, 60, and 90 minutes after topical 
antiglaucoma drop application in 30 healthy subjects. Corneal sensitivity was measured 
60 minutes before, and five, 10, and 15 minutes after drop application using a Cochet–Bonnet 
esthesiometer.
Results: Reduction of break-up time in the latanoprost group was -23.8% after 30 minutes 
(P = 0.21), -26.7% after 60 minutes (P = 0.03) and -51.4% after 90 minutes (P # 0.003), which 
was statistically significant. Reduction of break-up time in all other treatment groups was not 
statistically significant. The Jones test revealed a significant reduction of basal secretion after 
application of brimonidine (-17.8%, P = 0.002; -22.5%, P , 0.001; -30.5%, P , 0.001), fol-
lowed by apraclonidine (-10%, P = 0.06; -20.1%, P = 0.02; -22.1%, P = 0.002), latanoprost 
(-2.4%, P = 0.64; -18.6%, P = 0.001; -20.1%, P = 0.001) and dorzolamide (-0.5%, P = 0.9; 
14.3%, P = 0.018; -17.3%, P = 0.004) at 30, 60, and 90 minutes after drop application. Reduc-
tion of basal secretion in all other treatment groups was not statistically significant.
Conclusion: Latanoprost showed the most statistically significant reduction in break-up time, 
and brimonidine showed the most significant reduction in basal secretion of all the glaucoma 
medications used in this study. In conclusion, our data may be helpful for treatment decisions 
in glaucoma patients who also suffer from ocular surface problems.
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Introduction
Antiglaucoma medication is the major treatment modality for glaucoma. There is 
increasing evidence that topically administered medication affects the structure and 
the integrity of the ocular surface.1–4 Besides its intraocular pressure-lowering effect, 
local adverse effects, such as conjunctival hyperemia, foreign body sensation, or other 
symptoms of dry eye disease, can accompany its use. These symptoms can be related 
to the negative impact of topical antiglaucoma medication and its preservatives on 
tear-film stability. Because glaucoma therapy typically consists of long-term treatment, 
these symptoms usually become worse over the long term, eventually leading to a 
drop in compliance or to complete break-up of drop application in glaucoma patients. 
At this point, patient care and guidance suffer.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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In contrast with studies5,6 investigating their long-term 
effects on the ocular surface, quantitative investigations to 
evaluate the short-term effects of relatively “new” topical 
antiglaucoma medications on tear-film stability and corneal 
sensitivity are comparatively limited at the present time.
Therefore, the aim of this study was to investigate 
the short-term effect of the commonly used antiglaucoma 
  medications, ie, brimonidine, dorzolamide, latanoprost, 
timolol, and apraclonidine, as well as a fixed combination of 
dorzolamide and timolol, on tear-film stability, tear secretion, 
and corneal sensitivity in healthy subjects.
Methods and materials
Thirty healthy subjects were included in this prospective, 
double-blind, crossover study. The study protocol was 
approved by the ethics committee of Dresden in accordance 
with the Declaration of Helsinki. All subjects signed an 
informed consent form before participating in the study. 
Break-up time and a Jones test were performed 60 minutes 
before, and 30, 60, and 90 minutes after drop application. 
Corneal sensitivity was determined 60 minutes before, 
and 5, 10, and 15 minutes after topical drop application. 
In   accordance with the crossover design, all subjects 
received one topical medication, which was applied once 
into the lower fornix of the conjunctiva of one randomly 
chosen eye.   Additionally, benzalkonium chloride (BAK) 
0.02% and 0.005% and sodium chloride solution 0.9% 
as control substances were applied once in one randomly 
chosen eye.
Break-up time
For determination of break-up time, 10 µL of 0.2% 
  fluorescein solution was applied to the inferior fornix, and 
the participant was asked to close his/her eyes. Using the 
blue light of the slit lamp, the time in seconds between eyelid 
opening and the appearance of initial defects in the tear film 
was measured. Values longer than 10 seconds were accepted 
as reference with regard to high inter- and intraindividual 
variability.7
Corneal sensitivity
Corneal sensitivity was measured using a Cochet–Bonnet 
esthesiometer according to standard protocols.8 Briefly, the 
corneal surface was touched orthogonally with a defined 
nylon fiber. Eyelid closure was considered to be a positive 
response to the stimulus. The intensity of response was 
defined by the length and the stiffness of the fiber, which 
was then converted into pressure values.
Basal secretion
Measurement of basal secretion was performed according 
to the Jones test, but without mechanical irritation of the 
nasal mucosa.9 Sixty seconds after topical anesthesia with 
proxymetacain 0.5%, the tear film was sponged with a cotton 
swab, a standard test strip was placed in the outer third of 
the lower eyelid and then removed after five minutes, and 
the length of the moistened strip was measured. Despite 
considerable variability, results .20 mm were considered 
normal.10
statistical analysis
Statistical analysis was performed using SPSS software 
  (version 11.0, SPSS Inc, Chicago, IL). Data analysis of 
  follow-up examinations after five, 10, and 15 minutes 
  (corneal sensitivity) and after 30, 60, and 90 minutes 
(break-up time and basal secretion) were performed using 
analysis of variance for repeated measurements. In the 
event of a statistically significant difference, a t-test was 
performed to determine the time point at which a   significant 
difference from baseline examination was observed. Based 
on multiple testing for significant differences, the level 
of significance was adapted according to the Bonferroni 
method as follows: P = 0.05/3 = 0.017. P = 0.017 was 
therefore   considered statistically significant. Statistical 
analyses of results between the medications at different time 
points were performed using analysis of variance. Statisti-
cal significance was tested with post hoc analysis using the 
Bonferroni method to assess significant differences among 
the medications. In cases of significant differences in the test 
of homogeneity (Levene’s test), analysis of variance could 
not be performed, so the Kruskal–Wallis test was used for 
further statistical analysis.
Results
Thirty healthy subjects (16 women and 14 men) of mean 
age 32.1 ± 8.8 (range 19–59) years were included in 
this study.
Break-up time
Due to interindividual variability and for a better   comparability, 
measurement results were normalized to 100% and the 
  relative changes in break-up time were determined. Results 
of break-up time changes are shown in Figures 1 and 2. 
  Statistical analysis revealed no statistically significant 
  differences at 30, 60, or 90 minutes after drop   application 
among the different medications (P = 0.83, P = 0.87, 
P = 0.12, data not shown).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Analysis of significant differences of one medication dur-
ing the time course revealed statistically significant changes 
for latanoprost (P = 0.008), BAK 0.02% (P = 0.02), BAK 
0.005% (P = 0.039), and the fixed combination of dorzol-
amide and timolol (P = 0.015). The results for brimonidine 
(P = 0.24), sodium chloride 0.9% (P = 0.10), apraclonidine 
(P = 0.19), dorzolamide (P = 0.21), and timolol (P = 0.67) 
showed no statistically significant changes.
The strongest reduction of break-up time was observed 
after latanoprost application, with statistical significance 
after 90 minutes (-23.8% after 30 minutes, -26.7% after 
60   minutes, -51.4% after 90 minutes; P , 0.003). The fixed 
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Figure 1 Relative changes in break-up time of brimonidine, latanoprost, apraclonidine, dorzolamide, the fixed dorzolamide/timolol combination, and timolol 60 minutes 
before (T-60) and 30 (T+30), 60 (T+60), and 90 (T+90) minutes after drop application. 
Notes: *P , 0.05; **P , 0.01. 
Abbreviation: BUT, break-up time.
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Figure 2 Relative changes in break-up time of BAK 0.02%, BAK 0.005%, and sodium chloride 0.9% 60 minutes before (T-60) and 30 (T+30), 60 (T+60), and 90 (T+90) 
minutes after drop application. 
Note: *P , 0.05. 
Abbreviations: BUT, break-up time; BAK, benzalkonium chloride.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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combination of dorzolamide and timolol reduced break-up 
time at all time points, with statistical significance after 
90 minutes (-17.3%, P = 0.20; -18.3%, P = 0.10; -34.6%; 
P , 0.017). The change in break-up time in the BAK 0.02% 
group was -4.3% (P = 0.74) after 30 minutes, -6.5% (P = 0.67) 
after 60 minutes, and -39.1% (P , 0.003) at 90 minutes. In 
the BAK 0.005% group, the reductions were -3.6% (P = 0.71) 
after 30 minutes, -10.8% (P = 0.20) after 60 minutes, and 
-28.9% (P , 0.017) after 90 minutes. Break-up time after 
apraclonidine (-24.7%, -19.3%, -35.5%), brimonidine 
(-17.5%, -15.0%, -20.0%), dorzolamide (±0%, -8.2%, 
-21.2%), timolol (-2.2%, -16.3%, -7.6%), and sodium 
chloride 0.9% (-7.3%, 0%, 21.9%) showed trends towards 
reduction but did not reach statistical significance.
Basal secretion
Results of the basal secretion test are shown in Figures 3 
and 4. Similar to the case with break-up time, measurement 
results were normalized to 100%, and the relative changes in 
basal secretion were determined. Neither the baseline results 
(P = 0.99) nor the results after 30 minutes (P = 0.96), 60 min-
utes (P = 0.91), or 90 minutes revealed any   statistically signifi-
cant differences between the medications (data not shown).
Analysis of statistically significant differences associ-
ated with individual medications during the time course 
showed significant changes after application of   brimonidine 
(P , 0.001), latanoprost (P , 0.001), BAK 0.02% 
(P = 0.02), BAK 0.005% (P = 0.02), sodium   chloride 
0.9% (P = 0.02), apraclonidine (P , 0.001), and dorzol-
amide (P , 0.001). Basal-secretion changes after timolol 
(P = 0.09) and after the fixed combination of dorzolamide 
and timolol (P = 0.27) were not statistically significant. The 
strongest reduction in basal secretion was observed after 
brimonidine (-17.8%, P = 0.002 after 30 minutes; -22.5%, 
P , 0.001 after 60 minutes; -30.5%, P , 0.001 after 90 min-
utes), followed by apraclonidine (-10%, P = 0.06; -20.1%, 
P = 0.002; -22.1%, P = 0.002), latanoprost (-2.4%, P = 0.64; 
-18.6%, P = 0.0006; -20.1%, P = 0.001) and BAK 0.02% 
(-1.6%, P = 0.67; -13.1%, P = 0.03; -11.6%, P = 0.002), 
with a significant reduction after 90 minutes only.
Timolol (-4.7%; -8.6%; -14.3%) and the fixed 
  combination of dorzolamide and timolol showed a trend 
towards   reduction of basal secretion but did not reach 
  statistical significance. After adjustment of the P value, 
neither sodium chloride 0.9% (-6.7%, P = 0.24; -13.4%, 
P = 0.03; -14.4%, P = 0.03) nor BAK 0.005% (0%, P = 0.1; 
-10.1%, P = 0.13; -16.7%, P = 0.03) reached statistical 
significance. BAK 0.02% showed a significant reduction in 
basal secretion after 90 minutes (-1.6%, P = 0.67; -13.1%, 
P = 0.03; -11.6%, P = 0.002).
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Figure 3 Relative changes of basal secretion of brimonidine, latanoprost, apraclonidine, dorzolamide, the fixed combination dorzolamide/timolol and timolol 60 minutes 
before (T-60) and 30 (T+30), 60 (T+60) and 90 (T+90) minutes after drop application. 
Notes: *P , 0.05; **P , 0.01; ***P , 0.001. 
Abbreviation: Bs, basal secretion.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Corneal sensitivity
Similar to break-up time and basal secretion, measurement results 
were normalized to 100% and the relative changes of corneal 
sensitivity were determined. Figures 5 and 6 indicate the relative 
changes in corneal sensitivity five, 10, and 15 minutes after drop 
application in relation to baseline examination. Data analysis 
revealed no significant differences in corneal sensitivity between 
the different drops after five minutes (P = 0.59), 10   minutes 
(P = 0.69), or 15 minutes (P = 0.69, data not shown).
After five minutes, the strongest reduction in corneal 
sensitivity was observed after brimonidine and the fixed 
combination of timolol and dorzolamide (both -6.8%), but 
only after brimonidine was the reduction of corneal sensitiv-
ity statistically significant (P = 0.005). Latanoprost (-3.3%), 
dorzolamide (-1.7%), apraclonidine (-3.4%), and timolol 
(-3.4%) showed tendencies towards reduction of corneal 
sensitivity, but these were not statistically significant.
After 10 minutes, apraclonidine showed a significant 
reduction of -3.4% (P = 0.007). Latanoprost (-5.0%), dorzo-
lamide (±0.0%), timolol (-5.2%), and the fixed combination 
of timolol and dorzolamide (-5.1%) showed no significant 
reduction in corneal sensitivity.
After 15 minutes, only the fixed combination of dorzol-
amide and timolol (-5.1%) showed a significant reduction of 
corneal sensitivity (P = 0.01). Latanoprost (-3.3%), apraclo-
nidine (-1.7%), brimonidine (-1.7%), and timolol (-1.7%) 
showed no significant reduction. Dorzolamide showed no 
change of corneal sensitivity after 15 minutes (±0%).
Reductions of corneal sensitivity after BAK 0.02% 
(-1.7% after five minutes; ±0% after 10 minutes; -1.7% 
after 15 minutes), BAK 0.005% (-1.7%; 0%; -1.7%) and 
sodium chloride 0.9% (-1.7%; 0%; 0%) were not statisti-
cally significant.
No statistically significant results were found between 
men and women for break-up time, Jones test, or corneal 
sensitivity.
Discussion
Because glaucoma therapy represents a long-term treatment, 
symptoms usually become worse during the course of treat-
ment, eventually leading to a reduction in compliance or to 
break-up of drop application. This results from the negative 
effects of antiglaucoma medication and its preservatives on 
the corneal tear film,5,6 and these become worse with increas-
ing amounts of drops being applied. Recent studies investi-
gating the effect of topical antiglaucoma medication on tear 
secretion,11,12 tear-film stability,13,14 and corneal sensitivity15,16 
have mainly focused on the side effects of topical β-blockers. 
Quantitative investigations of relatively new antiglaucoma 
medications are limited at the present time. Therefore, this 
study was conducted to address this issue.
Latanoprost induced the highest reduction in break-up 
time, ie, to 50%. In contrast, Thygesen et al17 observed no 
changes in break-up time at 30 minutes and 28 days after 
latanoprost therapy. There are some methodological dif-
ferences between our study and the one by Thygesen et al 
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Figure 4 Relative changes of basal secretion of BAK 0.02%, BAK 0.005% and sodium chloride 0.9% 60 minutes before (T-60) and 30 (T+30), 60 (T+60), and 90 (T+90) 
minutes after drop application. 
Note: **P , 0.01. 
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Figure 5 Relative changes of corneal sensitivity of brimonidine, latanoprost, apraclonidine, dorzolamide, the fixed combination dorzolamide/timolol and timolol 60 minutes 
before (T-60) and 5 (T+5), 10 (T+10) and 15 (T+15) minutes after drop application. 
Note: *P , 0.05.
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Figure 6 Relative changes of corneal sensitivity of BAK 0.02%, BAK 0.005% and sodium chloride 0.9% 60 minutes before (T-60) and 5 (T+5), 10 (T+10) and 15 (T+15) 
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in that in our study, baseline measurement was performed 
one day before the first drop application, and the amount 
and concentration of fluorescein used was different in 
both studies (2.5 µL versus 10 µL and 1% versus 0.2%). 
Although latanoprost contains the highest amount of BAK 
(0.02%), the application of BAK alone led to a significant 
reduction of break-up time (40%), but not until 90 minutes 
had passed. After 30 and 60 minutes, no significant changes 
could be observed. As a consequence, it is conceivable that 
the high concentration of BAK is not only responsible for the 
reduction in break-up time but also of latanoprost itself. 
This finding is supported by the result for apraclonidine, 
containing BAK 0.01%, leading to a reduction of break-up 
time, although this was not statistically significant.
The short-term effect of preservative-containing timolol 
on break-up time showed a reduction of up to 16%, but 
this was not statistically significant. Strempel18 reported a 
reduction of 33% with both timolol and sodium chloride. 
The differences in percentage may be related to the time 
interval between drop application and the first break-up time 
  measurement (20 minutes versus 30 minutes). Additionally, 
the abovementioned study was not a randomized, double-
blind crossover study, but was an investigation of different 
groups of healthy subjects.
Break-up time was clearly higher after application of 
the fixed combination of dorzolamide and timolol than it 
was after application of dorzolamide and timolol separately. 
Even after taking the concentrations of BAK into account, 
and accounting for the approximately one-quarter higher 
BAK concentration than in the fixed combination, there 
is no reasonable explanation for our observation. It can 
only be assumed that the active agents themselves or other 
  contributing factors which are included in the original 
  substances are responsible for this effect on tear-film   stability, 
which is, of course, rather hypothetical and cannot be derived 
from our data.
The reduction of basal secretion was highest in the apra-
clonidine and brimonidine groups, which can be explained 
by vasoconstriction and the consequent water and electrolyte 
secretion by α-agonists.19 Moreover, α1-adrenergic receptors 
exist in lacrimal gland acinar cells, stimulating the secretion 
of proteins.20 However, it is not known whether activation of 
these receptors promotes an increase in tear secretion.
Basal secretion after latanoprost application was reduced 
significantly after 60 and 90 minutes (-18.6% and -20.1%, 
respectively). In contrast, in an animal model,   prostaglandin 
E1 showed a stimulating effect on tear secretion of the 
  lacrimal gland under the additional effect of β-receptors.21 
No change in tear secretion was observed by Thygesen et al17 
two hours after topical prostaglandin application, which is in 
contrast with our study results. However, there are three major 
factors which make a direct comparison of these two studies 
quite difficult. First, Thygesen et al performed Schirmer’s 
I test instead of the Jones test. Second, baseline measurement 
of basal secretion was conducted one day (versus 60   minutes) 
before drop application. Third, patients with primary open-
angle glaucoma and ocular hypertension, a mean age of 
69 years, and a drop abstention period of 3–4 weeks (versus 
healthy subjects with a mean age of 32 years) were included. 
Basal secretion was not significantly affected by the fixed 
combination of dorzolamide and timolol, which is surpris-
ing, because neither dorzolamide nor timolol alone induced 
a reduced basal secretion. There is no reasonable explanation 
for our observation, because sodium chloride and BAK in both 
concentrations affected basal secretion negatively.
Timolol induced a reduction in basal secretion (-14.3%) 
which was statistically significant after 90 minutes. Other 
studies have focused on the long-term effect of timolol on 
basal secretion. Merte and Merkle11 reported a reduction 
of 10.2% in basal secretion in 25 patients applying topical 
timolol in concentrations of 0.1% and 0.5% over two years. 
Other research reported reductions of 10%–25% in basal 
  secretion.22 In contrast, Kitazawa and Tsuchisaka did not find 
any reduction in basal secretion after 13 months of topical 
timolol application.23 However, a temporary reduction in 
basal secretion after one week of treatment, as measured by 
fluorometry, was observed by Gobbels et al which resolved 
after 4–7 months.24 Kuppens et al also observed a significant 
reduction of basal secretion in glaucoma patients after six 
months of timolol therapy, in contrast with basal secretion 
in healthy subjects.25
In our study, corneal sensitivity decreased by approxi-
mately 5% from baseline after 10 minutes. Höh observed 
a significant reduction in corneal sensitivity at one minute 
after a single application of timolol 0.5%. After minutes 3, 
6, 10, 15 and 30, no statistically significant changes were 
detected.26 Unfortunately, additional data about the short-
term effect of β-blockers are only available for pindolol, 
levobunolol, befunolol, metripranolol, carteolol, bupranolol, 
and betaxolol.27–31
Latanoprost showed a decrease of 5% in corneal sensi-
tivity after 10 minutes. In contrast, Thygesen et al did not 
detect any decrease in corneal sensitivity after 30 minutes 
or after 28 days.17Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Consistent with the findings of Kohlhaas et al32 in our 
study we found that dorzolamide caused a reduction in 
  corneal sensitivity after five, 10, and 15 minutes, but this was 
not statistically significant. In contrast with our study, the 
study by Kohlhaas et al32 determined measurements of   corneal 
sensitivity using an electronic-optical esthesiometer.
To the best of our knowledge, the present study is the 
first in which the effect of apraclonidine, brimonidine, 
and the fixed combination of dorzolamide and timolol on 
corneal sensitivity has been investigated. Brimonidine and 
the fixed combination of dorzolamide and timolol showed 
the strongest reduction in sensitivity, but only the changes 
after five minutes (brimonidine) and after 15 minutes (fixed 
combination) were statistically significant. The statistical 
significance of the fixed combination is surprising, because 
neither timolol nor dorzolamide showed a trend towards a 
reduction of sensitivity.
There are three major limitations in our study. First, the 
short-term effects of antiglaucoma medication on break-up 
time, basal secretion, and corneal sensitivity were investigated 
only in healthy patients. An extrapolation of our results to 
patients with glaucoma is limited, because glaucoma therapy 
is mainly a long-term treatment and, therefore, alterations of 
the ocular surface with disturbances of tear film-stability are 
also the result of long-term drop application. Nevertheless, in 
light of a negative additive effect on tear-film stability and a 
higher prevalence of dry eye disease in glaucoma patients,33 it 
is conceivable that our results, observed in young and healthy 
participants, are also relevant for glaucoma patients.
Second, the measurement techniques that we used in 
our study resulted in considerable inter- and intraindividual 
variability, which could have influenced the data analysis. 
However, we chose a double-blind, crossover design, and all 
antiglaucoma medications in our study were subject to the 
same measurement procedures and were used in an identical 
study population. The double-blindness of the study design 
reduced the subjective influence of both the investigator and 
the participant on measurement results.
Third, due to methodological differences compared 
with other studies and limited availability of reliable data, 
a   comparison of study results was difficult. Nevertheless, 
despite a certain heterogeneity in our study results, our 
data might be helpful for making treatment decisions for 
glaucoma patients who also suffer from ocular surface 
problems.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Broadway DC, Grierson I, O´ Brien C, Hitchings RA. Adverse effects 
of topical antiglaucoma medication I. The conjunctival cell profile. 
Arch Ophthalmol. 1994;112:1437–1445.
  2.  Steuhl KP, Knorr M, Frohn A, Thiel HJ. Effect of anti-glaucoma eye 
drops on cell differentiation of the conjunctiva. Fortschr Ophthalmol. 
1991;88:865–9. German.
  3.  Schwab IR, Linberg JV, Gioia VM, Benson WH, Chao GM. 
  Foreshortening of the inferior conjunctival fornix associated with 
chronic glaucoma medications. Ophthalmology. 1992;99:197–202.
  4.  Nuzzi R, Vercelli A, Finazzo C, Cracco C. Conjunctiva and subcon-
junctival tissue in primary open-angle glaucoma after long-term topical 
treatment: An immunohistochemical and ultrastructural study. Graefes 
Arch Clin Exp Ophthalmol. 1995;233:154–162.
  5.  Liesegang TJ. Conjunctival changes associated with glaucoma therapy: 
Implications for the external disease consultant and the treatment of 
glaucoma. Cornea. 1998;17:574–583.
  6.  Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term 
  morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s 
capsule in glaucomatous patients. Ophthalmology. 1989;96:327–335.
  7.  Zirm M. Schirmer test and break-up time. In: Marquardt R, editor. 
Chronic Conjunctivitis – Dry Eye. Wien, NY: Springer Verlag; 1982.
  8.  Cochet P, Bonnet R. L`estesie corneenne. Clin Ophthal. 1960;4:2–27.
  9.  Jones LT. The lacrimal secretory system and its treatment. Am J 
Ophthalmol. 1966;62:47–60.
  10.  Feldmann F, Wood MM. Evaluation of the Schirmer tear test. Can J 
Ophthalmol. 1979;14:257–259.
  11.  Merte HJ, Merkle W. Results of long-term treatment of glaucoma 
with timolol ophthalmic solution. Klin Monatsbl Augenheilkd. 
1980;177:562–571. German.
  12.  Petounis AD, Akritopoulos P. Influence of topical and systemic beta-
blockers on tear production. Int Ophthalmol. 1989;13:75–80.
  13.  Marquardt R, Schubert T. Modification of tear film break-up time by beta 
blocker eyedrops without preservatives. Klin Monatsbl Augenheilkd. 
1991;99:75–78. German.
  14.  Baudouin C, de Lunardo C. Short-term comparative study of topical 2% 
carteolol with and without benzalkonium chloride in healthy volunteers. 
Br J Ophthalmol. 1998;82:39–42.
  15.  Van Buskirk EM. Adverse reactions from timolol administration. 
Ophthalmology. 1980;87:447–450.
  16.  Höh H. The local anesthetic effect and subjective tolerance of 0.5% 
befunolol and 1% pindolol in healthy eyes. Klin Monatsbl Augenheilkd. 
1990;196:219–224. German.
  17.  Thygesen J, Aaen K, Theodorsen F, Kessing SV , Prause JU.   Short-term 
effect of latanoprost and timolol eye drops on tear fluid and the ocular 
surface in patients with primary open-angle glaucoma and ocular 
hypertension. Acta Ophthalmol. 2000;78:37–44.
  18.  Strempel I. Effect of commercial beta blockers and their combi-
nation with artificial tears on the duration of tear film stability. 
  Ophthalmologica. 1987;195:61–68.
  19.  Dartt DA. Signal transduction and control of lacrimal gland protein 
secretion: A review. Curr Eye Res. 1989;8:619–636.
  20.  Botelho SY, Martinez EV , Pholpramool C, Prooyen HC, Janssen JT, 
De Palau A. Modification of stimulated lacrimal gland flow by sym-
pathetic nerve impulses in rabbit. Am J Physiol. 1976;230:80–84.
  21.  Pholpramool C. Secretory effect of prostaglandins on the rabbit lacrimal 
gland in vivo. Prostaglandins Med. 1979;2:185–192.
  22.  De Popa DP, Andreescu G, Albu C. Tearing in a patient with glaucoma. 
Ophthalmologica. 1998;42:41–44.
  23.  Kitazawa Y, Tsuchisaka H. Effects of timolol on corneal sensitivity 
and tear production. Int Ophthalmol. 1980;3:25–29.
  24.  Gobbels M, Monks T, Spitznas M. Effect of topical 0.5% timolol on 
tear flow in patients with primary open-angle glaucoma as assessed by 
fluorophotometry. Ger J Ophthalmol. 1993;2:241–245.
  25.  Kuppens EV, Stolwijk TR, de Keizer RJ, van Best JA. Basal tear 
  turnover and topical timolol in glaucoma patients and healthy controls by 
fluorophotometry. Invest Ophthalmol Vis Sci. 1992;33:3442–3448.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
525
short-term effects of topical antiglaucoma medication
  26.  Höh H. Corneal sensitivity after single doses of timolol, betaxolol 
or placebo in persons with healthy eyes – a randomized,   prospective 
  double-blind study. Fortschr Ophthalmol. 1988;85:132–138. 
German.
  27.  Höh H. The local anesthetic effect and subjective tolerance of 0.5% 
befunolol and 1% pindolol in healthy eyes. Klin Monatsbl Augenheilkd. 
1990;196:219–224. German.
  28.  Höh H. Local anesthetic effect and subjective tolerance of 0.5% 
levobunolol in normal eyes. Klin Monatsbl Augenheilkd. 1990;197: 
20–26. German.
  29.  Höh H. Local anesthetic effect and subjective tolerance of 2% carteolol 
and 0.6% metripranolol on healthy eyes. Klin Monatsbl Augenheilkd. 
1989;194:241–248. German.
  30.  Bastian B, Höh H. Local anesthetic effect and subjective tolerance 
of a single dose of 0.25% bupranolol in probands with healthy eyes. 
A randomized parallel double-blind study. Klin Monatsbl Augenheilkd. 
1991;198:25–27. German.
  31.  Höh H. Corneal sensitivity after single doses of timolol, betaxolol 
or placebo in persons with healthy eyes – a randomized,   prospective 
  double-blind study. Fortschr Ophthalmol. 1988;85:132–138. 
German.
  32.  Kohlhaas M, Mammen A, Richard G. Change in corneal sensitivity 
after topical dorzolamide adminutesistration. A comparative study. 
Ophthalmologe. 1997;94:424–427. German.
  33.  Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related   quality 
of life in glaucoma patients. Eur J Ophthalmol. 2009;19:572–579.